A pharmaceutical composition for use in the prevention or treatment of diabetes or fatty liver comprising a compound represented by the following Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient: wherein R is phenyl or a 5 or 6 membered heteroaryl containing at least a heteroatom selected from the group consisting of N, O and S, which is unsubstituted or substituted with at least a substituent; the substituent is at least a subtituent selected from the group consisting of linear or branched C 1 -C 6 alkyl; heterocyclic ring or heteroaryl ring containing one or more heteroatoms in the ring and substituted with C 1 -C 6 alkyl or C 1 -C 6 alkylcarbonyl; C 2 -C 4 alkenylene substituted with halogen-substituted phenyl; C 1 -C 6 alkyloxycarbonyl; C 1 -C 6 alkyloxy; halogen; C 1 -C 6 alkyloxy substituted with C 1 -C 6 alkylamino group; hydroxycarbonyl C 1 -C 6 alkyl; C 1 -C 6 alkylamino; phenyl; phenyl substituted with at least a substituent selected from the group consisting of linear or branched C 1 -C 6 alkyl, linear or branched C 1 -C 6 alkyloxy, linear or branched C 1 -C 6 alkyloxycarbonyl, halogen atoms, and alkyl substituted with one or more fluoro atoms; phenoxy; phenoxy substituted with one or more substituents selected from the group consisting of linear or branched C 1 -C 6 alkyl, halogen atoms, and linear or branched C 1 -C 6 alkyloxy; aminosulfonyl; halo; cyano; acetyl; nitro; ethynyl; hydroxy; morpholino; naphthyl; thienyl; pyridyl; tetrahydrofuranyl; indolyl; indolyl substituted with linear or branched C 1 -C 6 alkyloxy; dihydrobenzooxynil; and furylmethylsulfanyl; and the aryl, heterocyclic ring and heteroaryl ring may be a heterocyclic structure in which two or more rings are fused, respectively, and may contain a carbonyl group in the ring. R is phenyl or a 5 or 6 membered heteroaryl containing at least a heteroatom selected from the group consisting of N, O and S, which is unsubstituted or substituted with at least a substituent; the substituent is at least a subtituent selected from the group consisting of linear or branched C 1 -C 6 alkyl; heterocyclic ring or heteroaryl ring containing one or more heteroatoms in the ring and substituted with C 1 -C 6 alkyl or C 1 -C 6 alkylcarbonyl; C 2 -C 4 alkenylene substituted with halogen-substituted phenyl; C 1 -C 6 alkyloxycarbonyl; C 1 -C 6 alkyloxy; halogen; C 1 -C 6 alkyloxy substituted with C 1 -C 6 alkylamino group; hydroxycarbonyl C 1 -C 6 alkyl; C 1 -C 6 alkylamino; phenyl; phenyl substituted with at least a substituent selected from the group consisting of linear or branched C 1 -C 6 alkyl, linear or branched C 1 -C 6 alkyloxy, linear or branched C 1 -C 6 alkyloxycarbonyl, halogen atoms, and alkyl substituted with one or more fluoro atoms; phenoxy; phenoxy substituted with one or more substituents selected from the group consisting of linear or branched C 1 -C 6 alkyl, halogen atoms, and linear or branched C 1 -C 6 alkyloxy; aminosulfonyl; halo; cyano; acetyl; nitro; ethynyl; hydroxy; morpholino; naphthyl; thienyl; pyridyl; tetrahydrofuranyl; indolyl; indolyl substituted with linear or branched C 1 -C 6 alkyloxy; dihydrobenzooxynil; and furylmethylsulfanyl; and the aryl, heterocyclic ring and heteroaryl ring may be a heterocyclic structure in which two or more rings are fused, respectively, and may contain a carbonyl group in the ring.